NextCure, Inc.
NXTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.03 | -0.07 | -0.03 |
| FCF Yield | -191.50% | -169.52% | -143.16% | -35.97% |
| EV / EBITDA | 0.00 | -0.39 | -0.27 | -2.30 |
| Quality | ||||
| ROIC | -82.89% | -55.53% | -43.24% | -30.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.84 | 0.72 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 23.26% | 3.94% | 6.04% | -14.43% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 0.10 | 0.27 | 0.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -919.03 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |